anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Uterine rupture is a life-threatening obstetric complication. The purpose of this study was to investigate the epidemiological features, maternal and foetal prognosis and different treatment options for uterine rupture in healthy and scarred uteri. We conducted a retrospective monocentric descriptive and analytical study of 60 cases of uterine rupture collected in the Department of Gynaecology-Obstetrics of the Center of Maternity and Neonatology, Monastir, from 2017 to 2021. Patients were classified according to the presence or absence of a uterine scar. Sixty patients were enrolled in the study. The majority of cases of rupture occurred in patients with scarred uterus (n=55). The most common clinical sign was abnormal foetal heart rate. No maternal deaths were recorded and perinatal mortality rate was 11%. Mean BMI, fetal macrosomia rate and mean parity were significantly higher in the healthy uterus group than in the scarred uterus group (p=0.033, 0.018, and 0.013, respectively). The maternal complications studied (post-partum haemorrhage, hysterectomy, blood transfusion, prolonged hospitalisation) were significantly more frequent in patients with unscarred uterine rupture (p=0.039; p=0.032; p=0.009; p=0.025 respectively). Uterine rupture is a life-threatening obstetrical event for the foetus and the mother. Fetal heart rate abnormality is the most common sign associated with uterine rupture. Management is based on conservative treatment in most cases. Patients with scarred uterus have a better prognosis.
BACKGROUND: To assess the predictive capabilities of serum exosomal levels of micro-RNA-520a-5p (miR-520a-5p) concerning the occurrence of severe preeclampsia (sPE) and fetal growth restriction (FGR) during the first trimester of pregnancy.
METHODS: During the period spanning from October 2020 to October 2021, serum samples were procured from the first trimester and subsequently preserved by freezing at -80 ℃. These samples were obtained from 105 pregnant women in a nested case-control study. This cohort consisted of individuals who later developed sPE (sPE group, n = 35) and FGR (FGR group, n = 35) during the third trimester. Additionally, 35 women with normal blood pressure were denoted as normal pregnancy group. Serum samples from the first trimester were retrieved from all groups for further analysis after thawing. Exosomes were extracted from the serum samples collected during the first trimester and examined using transmission electron microscopy, western blot, and nanoparticle tracking analysis. Additionally, the determination of their placental origin was also established during the course of the study. Exosome miR-520a-5p levels were measured using real-time quantitative polymerase chain reaction assays, primarily involving quantitative reverse transcription polymerase chain reactions. Fetal placental tissues from the 3 groups were collected shortly after birth, and miR-520a-5p expression was measured using real-time quantitative polymerase chain reaction. Serum placental exosomes and fetal placental tissues were compared for miR-520a-5p levels. Placental trophoblasts were identified as the source of serum exosomes in all 3 groups.
RESULTS: It was found that serum placental exosomes exhibited lower levels of miR-520a-5p in both the sPE and FGR groups when compared to the normal pregnancy group. This finding was consistent with observations made in postpartum placental tissues. The predictive accuracy for sPE using miR-520a-5p levels in serum placental exosomes during the first trimester was notably higher (area under the receiver operating characteristic curve = 0.806, P <.05) compared to the prediction of FGR (area under the receiver operating characteristic curve = 0.628, P <.05).
CONCLUSION: Placenta-derived exosomes can be extracted from maternal serum during the first trimester of pregnancy and miR-520a-5p detected from the exosomes. The downregulation of miR-520a-5p serves as a more predictive indicator for the subsequent development of sPE compared to predicting FGR.
Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye. After a 15 to 30 minutes break, same measurements repeated in the left eye.
The marine environment is a well-founded source for discovering a novel treatment method for numerous diseases. In the present invention, the anti-proliferative activity of Micromonospora butanol extract (MBE) associated with pro-oxidative activity in A549 and MCF7 cell lines was analyzed. The anti-proliferative effect was analyzed in vitro by treating cells with the MBE. In addition, a molecular mechanism underlying pro-apoptotic activity was also observed. A treatment with the MBE has been shown to decrease cell proliferation and increase an intracellular ROS. Based on a suppressed PI3K-AKT pathway, a switched BCL/BAD ratio and an increased caspase pathway, it has been found that the MBE induces apoptosis (apoptotic cell death) in A549 and MCF7 cell lines. Moreover, p38 and JNK phosphorylation were up-regulated by the treatment with the MBE in both cell lines. Taken together, these results suggest that the MBE acts as an anticancer agent through oxidative stress and JNK/MAPK pathway activity by enhancing apoptosis (apoptotic cell death) in the A549 and MCF7 cell lines.
The estrogen in Estradiol Valerate and Estradiol Valerate/Dienogest is estradiol valerate, a synthetic prodrug of 17ß-estradiol. 

The progestin in Estradiol Valerate and Estradiol Valerate/Dienogest is dienogest (DNG). DNG displays properties of 19-nortestosterone derivatives as well as properties associated with progesterone derivatives. [See Nonclinical Toxicology (13.2).]

###  Cardiac Electrophysiology

The effect of Estradiol Valerate and Estradiol Valerate/Dienogest on QT prolongation was evaluated in a randomized, double-blind, positive (moxifloxacin 400 mg) and negative (placebo) controlled crossover study in healthy subjects. A total of 53 subjects were administered Estradiol Valerate and Estradiol Valerate/Dienogest (containing 3 mg dienogest and 2 mg estradiol valerate), dienogest 10 mg, and placebo as once daily doses for 4 days, and moxifloxacin 400 mg as a single oral dose. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc based on Fridericia’s correction method (QTcF) was below 10 msec, the threshold for regulatory concern.
FIELD: polymers, cosmetics. SUBSTANCE: invention relates to a stable polyorganosiloxane gel comprising gel-bound hydrophilic groups. These groups are prepared by hydroxylation reaction of unsaturated polyorganosiloxane resin, cross-linking agent carrying hydrogen atom- -linked with groups S i -H and hydroxylable unsaturated hydrophilic substance in the presence of effective amount of the hydroxylation reaction catalyst. At least part of this reaction occurs in the presence of at least 60 wt.-% of oily composition comprising at least 50 wt.-% of low-viscous polyorganosiloxane. By effect of shifting strength cross-linked organosiloxane compositions form stable preferably noncompatible gel that can be used , in turn, for preparing stable emulsion with large amounts of usually noncompatible hydrophilic liquids. Invention relates also to method for preparing polyorganosiloxane gel, homogenous stable emulsion and cosmetic product also. Invention provides to prepare viscosity-free gel from early available and practically nontoxic components that cane be emulsified without usage of units with extremely high pressure and without prolonged highly shifting moving that is able also for preparing cosmetic products no forming oiliness perception after their application on jacket or film. EFFECT: improved preparing method, valuable properties of gel. 18 cl, 5 tbl, 33 ex
In recent years, increased attention has been devoted to intergenerational physical activity (PA) programs because they may have several benefits for children and older adults (e.g., learning skills from each other, reduction of ageism). An intergenerational PA program focusing on grandchildren and -parents in a 'standard' family setting and the combination of PA and cognitive functions is innovative and may hold potential to promote PA and improve cognitive functions in both grandchildren and their grandparents. The aim of this study is to describe the protocol of the GRANDPACT (GRANDparents and GRANDchildren improve their Physical Activity and Cognitive functions using co-creaTion) project, focusing on the development of an intergenerational PA program for grandchildren and -parents using the theoretical framework "Behaviour Change Wheel" in combination with a co-creation approach. One co-creation trajectory will be organized to develop the program, followed by an efficacy trial to refine and evaluate the program with measurements pre (at baseline), post (after 24 weeks) and follow-up (after 36 weeks) to measure the outcomes of (co-)PA, cognitive functions, psychosocial well-being, the quality of the family relationship, expectations regarding aging and motor competence in grandchildren and -parents. The outcomes will be measured using accelerometery for PA, Cambridge Neuropsychological Test Automated Battery (CANTAB) testing for cognitive functions and questionnaires for psychosocial well-being, quality of the family relationship and expectations regarding aging. Motor competence will be tested with different field tests in grandparents and grandchildren. Co-development with end-users and stakeholders during the co-creation trajectory is expected to result in an effective, attractive and feasible program. Co-PA is expected to improve PA, cognitive functions, psychosocial well-being, quality of the family relationship, motor competence and motivation to be physically active in grandchildren and -parents. Both will also have better expectations regarding aging.
NEW MATERIAL:An antibody exhibiting extremely high specific reactivity to either of IgG and IgM of human antibody. USE:Useful for the remedy of human disease and diagnosis by imaging. A reagent useful for the removal or recovery of human antibody from human serum. PREPARATION:A small experimental animal is immunized with a mixed material containing human antibody (e.g. human gamma-globulin). A lymphocyte obtained from the immunized animal is fused with a myeloma cell to obtain a hybridoma. The hybridoma is cloned and the established hybridoma strain is cultured in a peritoneal cavity of a small experimental animal to produce the objective antibody.
Preparations from aromatic plants that are insecticidal or are insect behaviorally active, are used to control the development of insect populations. The plants are harvested after leaf maturation. Leaves are removed in a random pattern both as to individual plants and to location of leaves on each plant. The collection includes petioles but not stems. Leaves are milled with or without drying to a small average particle size. Extracts and vapors may also be used. The resultant preparation, when contacted with dry commodities infested with storage insects or with insect infested perishable produce after harvest will reduce the insect population.
FIELD: medicine. SUBSTANCE: invention proposes the potentiated form of brain-specific protein S-100 taken in hundredth dilution C1-C10000. Agent shows the broad spectrum of action (sedative, tranquilizing, nootropic, psychoactive, antipsychotic, antiabstinent in alcoholism and narcomania). Agent can be used for correction of damaged immune homeostasis accompanying with alteration of psychosomatic functions and/or biological responses based on multiple effect on integrative activity of brain. EFFECT: enhanced effectiveness of agent, valuable medicinal properties, absence of adverse symptoms. 2 cl, 7 ex
The present invention relates to a celecoxib solid dispersion and its preparation method. The solid dispersion of the invention comprises of celecoxib and carrier materials selected from one or more of polyvinylpyrrolidone, copovidone, polyvinylpolypyrrolidone, and the weight ratio of scaffold material/celecoxib can be low to 0.2: 1. It is prepared in the way that carrier materials and celecoxib are dissolved or dispersed in organic solvents, and then the organic solvent is removed by vacuum distillation or spray drying. The solid dispersion which is subjected to crush can be easily made into all kinds of solid dosage forms. The problem that celecoxib crude drug is difficult to smash is well solved by the invention. Furthermore, the solid formulations of the invention can be made by using few materials, and have a good stability and high bioavailability.
Women randomized to the "connected device" arm will follow a 6-month exercise program using a connected device that includes an activity tracker and subscription to an exercise and physical activity management program through a smartphone application and a website. They will also receive international recommendations on physical activity.
To develop a nomogram model for predicting contralateral patent processus vaginalis in children with unilateral inguinal hernia or hydrocele. A retrospective analysis was conducted on 259 children with unilateral inguinal hernia or hydrocele who underwent laparoscopic surgery at the Southern Hospital of Southern Medical University from January 2021 to December 2023. The patients were randomly divided into a training set (n = 207) and a validation set (n = 52) in an 8:2 ratio to analyze the characteristics of CPPV. Multivariate logistic regression analysis was used to screen for independent risk factors for CPPV, and a nomogram prediction model was constructed. The predictive ability, calibration, and clinical net benefit of the model were evaluated by plotting receiver operating characteristic (ROC) curves, calibration curves (HL), and clinical decision curves (DCA). Among children under 1 year old, the laparoscopic exploration revealed a CPPV incidence rate of 55.17%. The incidence rates for children aged 2-10 years ranged from 29.03 to 39.13%, and the incidence rate for children aged 11-14 years was 21.21%. Multivariate logistic regression analysis showed that age (OR = 0.9, 95%CI 0.82-0.99, P = 0.035) and female gender (OR = 2.42, 95%CI 1.21-4.83, P = 0.013) were independent risk factors for CPPV, and the incidence of CPPV decreased with age. The area under the ROC curve (AUC) for the training set of the constructed model was 0.632, and the AUC for the validation set was 0.708. The Hosmer-Lemeshow goodness-of-fit test indicated good model fit (training set P = 0.085, validation set P = 0.221), and the DCA curve suggested good clinical benefit.The nomogram model developed in this study demonstrates good clinical value. Children with unilateral inguinal hernia or hydrocele who are younger in age and female gender should undergo careful intraoperative exploration for the presence of CPPV. What is Known: • The probability of developing inguinal hernia in children with CPPV is 11%-25%, and redo surgery can increase surgical risks and financial burden. • The risk factors of unilateral inguinal hernia combined with CPPV are controversial. What is New: • Age and female gender are independent risk factors for CPPV. • A nomogram prediction model was constructed to provide a theoretical basis as well as an assessment tool for preoperative evaluation of whether children with unilateral indirect inguinal hernia are susceptible to CPPV.
PROBLEM TO BE SOLVED: To obtain a hair-growing tonic exhibiting an excellent hair growth- prompting activity. SOLUTION: This hair-growing tonic is obtained by incorporating (A) one kind of compound selected from hair growth-prompting agents and (B) at least one kind selected from plant extracts of the following (1) to (6). (1) A plant belonging to the genus Rehmannia of Scrophulariacea. (2) A plant belonging to the genus Zizyphus of Rhamnaceae. (3) A plant belonging to the genus Ganoderma of Polyporaceae. (4) A plant belonging to the genus Luffa of Cucurbitaceae. (5) A plant belonging to the genus Poria of Polyporaceae. (6) A plant belonging to the genus Crataegus of Rosaceae.
BACKGROUND: Physical inactivity, which is highly prevalent in patients with systemic lupus erythematosus (SLE), is an independent risk factor for cardiovascular events and causes many complications. This study aimed to investigate the effect of objective measurement and physical activity level on peripheral muscle strength, exercise capacity, pain, dyspnea, fatigue, anxiety, and depression in patients with SLE.
METHODS: The present cross-sectional study analyzed 41 patients with SLE. Clinical and demographic characteristics of patients were recorded. Functional exercise capacity, peripheral muscle strength, dyspnea, pain, fatigue, anxiety, and depression were assessed. The physical activity level was assessed by a wearable activity tracker (Mi Band four smart band).
RESULTS: The number of steps measured by the activity tracker was 4384.43 ± 1558.21 steps per day in patients with SLE. Patients with physical activity levels below 5000 steps exhibited elevated levels of fatigue, along with diminished functional exercise capacity and knee muscle strength, in comparison to those who were above the 5000-step threshold. Physical activity levels correlated with functional exercise capacity (6MWT), physiological parameters (maximum heart rate, Δ heart rate, Δ dyspnea, QFM fatigue, Δ QFM fatigue), and knee extension muscle strength. The functional exercise capacity and knee extension were identified as significantly and dependently associated with physical activity levels in SLE patients.
CONCLUSION: Physical activity level is associated with functional exercise capacity and knee muscle strength in patients with SLE.
The invention belongs to the field of classification of medical images, and particularly relates to a small sample colorectal cancer analysis method and system based on priori guidance feature enhancement. In the absence of high quality medical datasets, colorectal cancer staging algorithms are constructed with a small number of samples. The invention adopts a double encoder structure to train on public images and target medical data respectively, and extracts general features and specific features from colorectal cancer medical images. The introduction of a priori guided Variational Automatic Encoder (VAE) module aligns feature vectors with their priors in potential space, enhancing the robustness of the target features. And matching target features of sample extraction in the support and query set based on a maximum a posteriori probability (MAP) algorithm, and predicting the number of the cancer period of the query sample. The method can remarkably improve the accuracy of small sample colorectal cancer medical image segmentation, solves the limitation of a small sample medical classification algorithm to a certain extent, and reduces the cost of manual marking.
The LIA group will utilize weight based dosing of Ropivacaine as part of a "cocktail" solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia.
BACKGROUND: Macular retinoschisis (MRS) and myopic macular neovascularization (mMNV) are both potentially blinding complications of high myopia. In this case report, we highlight the progression of MRS after intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for mMNV, as well as an extensive review of the literature on this topic.
CASE DESCRIPTION: A 49-year-old woman presented with two weeks of recent onset blurring and metamorphopsia in her right eye. She had high myopia in both eyes (right eye - 20/60 with - 16D, left eye - 20/20 with - 13D). Slit-lamp ophthalmoscopy found a normal anterior segment in both eyes. On fundus examination, features of pathological myopia with posterior staphyloma and peripapillary atrophy were observed in both eyes. An active mMNV, as well as intraretinal fluid, minimal perifoveal inner and outer MRS, and focal posterior vitreous traction along the inferotemporal retinal arcade, were detected on optical coherence tomography (OCT) of the right eye. The patient received an intravitreal injection of Aflibercept (2 mg/0.05 ml).
RESULTS: OCT scans at two- and four-month follow-up visits revealed regressed mMNV with a taut epiretinal membrane, progressive worsening of outer MRS, and the development of multiple perifoveal retinal detachment inferior to the fovea. Pars plana vitrectomy surgery was performed for the progressive MRS with good anatomical (resolved MRS) and functional outcome (maintained visual acuity at 20/60) at the last one-month post-surgery visit.
CONCLUSION: Intravitreal anti-VEGF injections for mMNV can cause vitreoretinal interface changes, exacerbating MRS and causing visual deterioration. Vitrectomy for MRS could be one of several treatment options.
PCT No. PCT/JP97/01906 Sec. 371 Date May 11, 1998 Sec. 102(e) Date May 11, 1998 PCT Filed Jun. 5, 1997 PCT Pub. No. WO97/46677 PCT Pub. Date Dec. 11, 1997The present invention provides for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of the distribution of helper T-cell subsets Th1 and Th2. More sepcifically, in this invention, the gene (B19) specific only the human Th2 is prepared and specified by a subtraction method, and a recombinant vector into which the gene is incorporated, a transformant transformed by the recombinant vector, a human-Th2-specific protein which the gene encodes and which derives from the transformant, and a monoclonal antibody against the Th2-specific protein are produced and the gene, protein, antibody, etc. are used as the means for specifying or correcting the polarization of the distribution of Th1 and Th2 to solve the above object.
Adult subjects with epilepsy will undergo noninvasive video Electroencephalography (EEG) and intracranial electrodes sampling the amygdala and hippocampus (unilateral or bilateral). A subset of subjects (n=10) will use the Context-Aware Multimodal Ecological Research and Assessment (CAMERA) platform for 2 weeks after discharge with a subset of modalities: physiologic wristband, smartphone phenotyping, ecological momentary assessment (EMA) surveys, and memory task. At unpredictable intervals, CAMERA will interrupt subjects with: (a) an audible alarm to elicit an acoustic startle response; (b) a self-reported anxiety state scale; and (c) a visuospatial memory task with threat interference. For example, participants will fill out a brief survey and play a video game several times each day and wear a wristband with sensors.
PURPOSE: A patient monitoring system of a wireless remote communication method for medical treatment is provided to effectively manage vital signs of patients by selecting a channel of a limited frequency band and maintaining a stable wireless data communication environment. CONSTITUTION: A sensor(11) collects a vital sign of a patient. A converter(150) converts a frame format of a digital type into an analog signal. A channel setting switch(124) receives a selection signal about the set channel. A communication device(100) transmits an RF signal by wireless. A mixer(140) filters an analog signal including the frame format. A data processing unit(122) confirms a vital sign.
Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m\^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
Intervention: Carboplatin + paclitaxel + pembrolizumab + lenvatinib for 3 weeks (21 days) as 1 cycle, up to a maximum of 4 cycles in the induction phase. Then, maintenance therapy with pembrolizumab and lenvatinib will be continued until progression or unacceptable adverse events up to 31 cycles.
Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.